论文部分内容阅读
目的观察垂体后叶素雾化吸入治疗支气管扩张咯血的效果与副作用。方法将66例支气管扩张咯血病人随机分为治疗组34例和对照组32例,治疗组在常规治疗的基础上给予垂体后叶素6 U加生理盐水3 m l氧气驱动雾化吸入,每日4次,每次10~15 m in;对照组在常规治疗的基础上给予垂体后叶素0.1 U.kg-1.h-1静脉滴注。2组疗程均为3 d(如3 d后仍有大咯血则改行支气管动脉栓塞疗法)。观察2组治疗效果、咯血停止时间及副作用发生率。结果治疗组与对照组临床总有效率分别为94.12%和93.75%,差异无统计学意义(P>0.05);咯血停止时间分别为(1.88±1.02)、(1.79±1.11)d,差异无统计学意义(P>0.05);治疗组各种副作用发生率均明显低于对照组(P均<0.05)。结论垂体后叶素雾化吸入治疗支气管扩张咯血与静脉应用疗效无显著差异,但副作用明显减少,值得临床推广。
Objective To observe the effect and side effects of vasopressin inhalation on bronchiectasis hemoptysis. Methods 66 patients with bronchiectasis hemoptysis were randomly divided into treatment group (34 cases) and control group (32 cases). On the basis of routine treatment, the treatment group was given puerarin 6 U plus normal saline 3 ml oxygen inhalation, daily 4 Times, each 10 ~ 15 m in; control group on the basis of conventional treatment given pituitrin 0.1 U.kg-1.h-1 intravenous drip. The duration of treatment was 3 days in both groups (bronchial artery embolization was switched to if hemoptysis was still present after 3 days). Two groups were observed the treatment effect, the time of hemoptysis and the incidence of side effects. Results The total clinical effective rates in the treatment group and the control group were 94.12% and 93.75%, respectively, with no significant difference (P> 0.05). The durations of halting hemoptysis were (1.88 ± 1.02) and (1.79 ± 1.11) days, respectively, with no statistical difference (P> 0.05). The incidence of various side effects in the treatment group was significantly lower than that in the control group (all P <0.05). Conclusions There is no significant difference in therapeutic effect between vasopressin inhalation and bronchodilator hemoptysis on venous application, but the side effects are obviously reduced, which deserves clinical promotion.